- Ebos notified on Tuesday that its retail offer of up to NZ$105 million for eligible existing shareholders will end on 17 January 2022.
- The Retail offer is part of the equity raising plan of Ebos to acquire LifeHealthcare.
Largest and the most diversified wholesale distributor and marketer of healthcare, pharma products EBOS Group Limited (NZX:EBO) notified on Tuesday that its retail offer of up to NZ$105 million for eligible existing shareholders will end on 17 January 2022.
Eligible shareholders will be able to invest up to a maximum of NZ$50,000 in new shares of the Company.
Image source: © 2021 Kalkine Media®
The Group had announced on 15 December 2021 that it is opening up a retail offer to raise nearly NZ$105 million with the ability to accept oversubscription as well on the Company’s direction. The Retail Offer is a part of the Company’s equity raising that was announced on 9 December 2021.
EBOS has planned to acquire medical device distributor LifeHealthcare for a total consideration of nearly NZ$835 million that will be financed partly by share placement, retail offer, term loan debt facility and issue of new EBOS shares to LifeHealthcare.
EBOS will purchase 100% of LifeHealthcare’s Australian and New Zealand subsidiaries along with 51% of Transmedic, its Asian subsidiary, as per the terms of the contract.
On 11 January, at the time of writing, EBO was trading at NZ$40.32, up 1.18%.
The acquisition of LifeHealthcare would permit EBOS to fast-track its medical devices methodology and expand its current portfolio.